Physician profile
Jon Wesley Walker
NPI 1023085032
$545.47
in general payments reported to CMS, 2019-2025
14 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.17 · 2022: $40.79 · 2023: $133 · 2024: $29.65 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.01 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.18 | 2022-2023 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $92.45 | 2025 | Rexulti |
| Mannkind Corporation | $57.08 | 2025 | |
| Abbott Laboratories | $55.60 | 2025 | Aveir |
| Exact Sciences Corporation | $41.65 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $35.18 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $29.43 | 2024-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $19.81 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $18.46 | 2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.12 | 2025 | Xifaxan |
| Medicem INC. | $17.50 | 2022 | |
| Verastem, INC. | $16.17 | 2019 | |
| Antares Pharma, INC. | $15.26 | 2024 | Xyosted |
| Axsome Therapeutics, INC. | $10.58 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.